Regeneron a 'national strategic asset' for quick response to COVID-19 outbreak: analyst

regeneron
Despite Regeneron's inside track on a COVID-19 treatment, the virus could spell trouble for blockbuster Eylea's sales. (Regeneron)

Drugmakers of all shapes and sizes are chasing after therapeutics and vaccines to fight the novel coronavirus. But among the pack, one company's track record might give it the jump on a treatment—and at least one analyst is not afraid to heap praise on its efforts. 

Regeneron's "innovative horsepower and initiative" in its response to COVID-19, including a push to repurpose arthritis med Kevzara and quickly identify new antibodies to target the virus, has put the drugmaker in the lead to develop a treatment, Evercore ISI analyst Josh Schimmer said in a note to investors Friday.

After a luncheon with CEO Len Schleifer, Schimmer touted Regeneron's response not only to COVID-19 but also Ebola as a "national strategic asset" for the U.S. given the drugmaker's quick mobilization in outbreaks.

Featured Webinar

How to Streamline Your Clinical Research Organization's Processes End to End

Learn how implementing one platform leads to data consistency and ultimately facilitate faster clinical trials while reducing overall trial costs, leave behind spreadsheets and home-grown tools for a predictable trial and the ability to forecast unit delivery resulting in the optics you need to ensure a successful trial, and hear experts share industry trends of what is affecting the Clinical Research Organization industry today.

"Our most important takeaway is that the COVID pandemic is a lesson of how lucky the country is to have (Regeneron)––it is poised to perhaps have the biggest impact on this outbreak," Schimmer wrote. 

RELATED: Could arthritis med Kevzara hold promise against the novel coronavirus? Sanofi, Regeneron aim to find out

Suggested Articles

The only thing certain about 2020 has been uncertainty, leaving almost everyone wondering what might come next.

Operation Warp Speed co-leader Moncef Slaoui is worried that political rhetoric will dissuade Americans from getting vaccinated against COVID-19.

Dr. Reddy’s Laboratories has shut 'key' plants worldwide and all data center services as a preventive measure after detecting a data breach.